BCRX BIOCRYST PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, BIOCRYST PHARMACEUTICALS INC reported revenue of $218M (up 33.6% from a year earlier), net income of $78.4M and diluted EPS of $0.30; over the last four quarters revenue was $941M and net income −$385M; for the fiscal year ended December 2025 revenue was $875M, up 94.1% on the year before.

BCRX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $875M, gross profit n/a, operating income $341M, net income $264M (margin 30.2%), EPS $1.21
• Fiscal year ended Dec 2024: revenue $451M, gross profit n/a, operating income −$2.54M, net income −$88.9M (margin -19.7%), EPS −$0.43
• Fiscal year ended Dec 2023: revenue $331M, gross profit n/a, operating income −$104M, net income −$227M (margin -68.4%), EPS −$1.18
• Fiscal year ended Dec 2022: revenue $271M, gross profit n/a, operating income −$148M, net income −$247M (margin -91.2%), EPS −$1.33
• Fiscal year ended Dec 2021: revenue $157M, gross profit n/a, operating income −$178M, net income −$184M (margin -117.1%), EPS −$1.03

BCRX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $218M (up 33.6% year over year), net income $78.4M, EPS $0.30
• Quarter ended Mar 31, 2026: revenue $156M (up 7.5% year over year), net income −$722M, EPS −$2.98
• Quarter ended Dec 31, 2025 (from the annual report): revenue $407M (up 209.1% year over year), net income $246M, EPS $1.13
• Quarter ended Sep 30, 2025: revenue $159M (up 36.1% year over year), net income $12.9M, EPS $0.06
• Quarter ended Jun 30, 2025: revenue $163M (up 49.4% year over year), net income $5.09M, EPS $0.02
• Quarter ended Mar 31, 2025: revenue $146M (up 56.9% year over year), net income $32.0K, EPS $0.00
• Quarter ended Dec 31, 2024 (from the annual report): revenue $132M (up 40.8% year over year), net income −$26.8M, EPS −$0.13
• Quarter ended Sep 30, 2024: revenue $117M (up 35.0% year over year), net income −$14.0M, EPS −$0.07
• Quarter ended Jun 30, 2024: revenue $109M (up 32.5% year over year), net income −$12.7M, EPS −$0.06
• Quarter ended Mar 31, 2024: revenue $92.8M (up 34.9% year over year), net income −$35.4M, EPS −$0.17
• Quarter ended Dec 31, 2023 (from the annual report): revenue $93.4M (up 17.4% year over year), net income −$61.7M, EPS −$0.31
• Quarter ended Sep 30, 2023: revenue $86.7M (up 14.4% year over year), net income −$36.1M, EPS −$0.19
• Quarter ended Jun 30, 2023: revenue $82.5M (up 25.9% year over year), net income −$75.3M, EPS −$0.40
• Quarter ended Mar 31, 2023: revenue $68.8M (up 37.8% year over year), net income −$53.3M, EPS −$0.28
• Quarter ended Dec 31, 2022 (from the annual report): revenue $79.5M (up 68.7% year over year), net income −$71.5M, EPS −$0.38
• Quarter ended Sep 30, 2022: revenue $75.8M (up 85.0% year over year), net income −$42.5M, EPS −$0.23
• Quarter ended Jun 30, 2022: revenue $65.5M (up 31.2% year over year), net income −$58.9M, EPS −$0.32
• Quarter ended Mar 31, 2022: revenue $49.9M (up 161.9% year over year), net income −$74.2M, EPS −$0.40
• Quarter ended Dec 31, 2021 (from the annual report): revenue $47.2M, net income −$17.8M, EPS −$0.10
• Quarter ended Sep 30, 2021: revenue $41.0M, net income −$58.8M, EPS −$0.33

BCRX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow $347M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$52.0M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$95.1M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$162M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$142M, share buybacks n/a

BCRX balance sheet

• Jun 30, 2026: cash $155M, total assets $558M, total liabilities $1.01B, shareholders' equity −$454M, long-term debt $395M
• Mar 31, 2026: cash $172M, total assets $465M, total liabilities $1.02B, shareholders' equity −$554M, long-term debt $395M
• Dec 31, 2025: cash $89.7M, total assets $514M, total liabilities $633M, shareholders' equity −$119M, long-term debt $0
• Sep 30, 2025: cash $84.1M, total assets $446M, total liabilities $834M, shareholders' equity −$388M, long-term debt $194M
• Jun 30, 2025: cash $88.0M, total assets $457M, total liabilities $879M, shareholders' equity −$422M, long-term debt $243M
• Mar 31, 2025: cash $105M, total assets $480M, total liabilities $932M, shareholders' equity −$452M, long-term debt $315M
• Dec 31, 2024: cash $105M, total assets $490M, total liabilities $966M, shareholders' equity −$476M, long-term debt $315M
• Sep 30, 2024: cash $96.8M, total assets $491M, total liabilities $960M, shareholders' equity −$469M, long-term debt $314M

What is BCRX's revenue?

BIOCRYST PHARMACEUTICALS INC reported $941M of revenue over its last four quarters, through June 30, 2026.

Is BCRX profitable?

No. BIOCRYST PHARMACEUTICALS INC lost $385M over the last four quarters.

What is BCRX's EPS?

Diluted earnings per share over the last four quarters were −$1.49; $0.30 in the latest quarter.

BCRX ownership and insider trades · All stocks